Cardiothoracic & vascular anesthesia
Landiolol for the prevention of postoperative atrial fibrillation after cardiac surgery: a systematic review and meta-analysis
Authors' conclusion
In patients undergoing cardiac surgery, landiolol likely reduces POAF and may reduce LOS.
Study context
- Population
- Patients undergoing cardiac surgery
- Participants
- 868 patients · 9 randomized controlled trials (RCTs)
- Comparison
- Landiolol vs control
- Landiololn = 460
- Controlsn = 408reference
- Outcome
- Postoperative atrial fibrillation (POAF)
Methodological detailsrandom-effects models, GRADE certainty assessment
- Random-effects models
- GRADE certainty assessment
Pooled result
As reported in the abstract
Landiolol vs ControlsRelative risk (95% CI)
I2 = 0%
0.40(0.30–0.54)
Landiolol vs ControlsAbsolute risk difference (95% CI)
POAF
20.4%(15.0–25.0)
Further pooled results
| Outcome | Mean difference (days) (95% CI) | |
|---|---|---|
| Hospital LOS268 patients; I2 = 0% · low certainty (imprecision, reporting bias) | −2.32 (−4.02 to −0.57) | |
| −6−4−202Difference, days (linear scale) |
Safety
Bradycardia
- No significant difference in bradycardia
- RR, 1.11; 95% CI, 0.48 to 2.56
- I2 = 0%
Hypotension
- No hypotension reported with landiolol
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Landiolol for the prevention of postoperative atrial fibrillation after cardiac surgery: a systematic review and meta-analysis. Can J Anaesth. Published 2 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →